Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 13;8(12):e1674113. doi: 10.1080/2162402X.2019.1674113

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Taylor & Francis Group, LLC

PMC Copyright notice

Figure 2. — Survival in patients with ESFT is dependent on the abundance of immune cell types.

Kaplan-Meier analyses showing OS and EFS with tumors with low (blue) and high (red) frequency of specific immune cells determined by CIBERSORT, as indicated: (a, b, c) OS analysis. (d, e, f) EFS analysis. Thirty-two patients within the training cohort (GSE17679) were included in this survival analysis. (a) Low frequency of neutrophils in ESFT (<0.2546% of total immune cells) were associated with a good prognosis (median OS not reached), high frequency of neutrophils (>0.2546% of total immune cells) with an estimated median survival of only 20.7 months (95% CI 11.9–29.5 months) (p = .038). (b) High frequency of activated NK cells (>3.771% of total immune cells) were associated with a good prognosis (median OS not reached), low frequency of activated NK cells (<3.771% of total immune cells) with an estimated median survival of only 20.7 months (95% CI 12.1–29.3 months) (p = .007). (c) High frequency of total T cells (>22.43% of total immune cells) were associated with a good prognosis (median OS not reached), low frequency of total T cells (<22.43% of total immune cells) with an estimated median survival of only 21.3 months (95% CI 12.1–30.5 months) (p = .044). (d) Whereas patients ESFTs with a low frequency of M2 macrophages (<24.83% of total immune cells) had a median EFS of 47 months, high frequency of M2 macrophages (>24.83% of total immune cells) were associated with an estimated median survival of only 15.3 months (95% CI 8.6–22.0 months) (p = .033). (e) Low frequency of memory B cells (<8.655% of total immune cells) were associated with a median EFS of 28.6 months (95% CI 0.8–56.4 months), high frequency of memory B cells (>8.655% of total immune cells) with an estimated median survival of only 11.7 months (95% CI 7.5–15.9 months) (p = .024). (f) High frequency of total T cells (>22.43% of total immune cells) were associated with a median EFS of 47 months, low frequency of total T cells (>22.43% of total immune cells) with an estimated median survival of only 14 months (95% CI 6.9–21.1 months) (p = .032). Log-rank test.